CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will release its first-quarter 2025 financial results on Thursday, May 1, 2025, before U.S. markets open. Management will host a live ...

Madrigal Pharmaceuticals (MDGL) announced that Rebecca Taub, M.D., the company’s founder, Chief Medical Officer, and President of Research ...

CONSHOHOCKEN, Pa., April 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction ...

In this article, we are going to take a look at where Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) stands against other most expensive stocks insiders are dumping in March. After being in the ...

Madrigal Pharmaceuticals Stock Down 4.1 % MDGL opened at $307.78 on Thursday. The company has a 50 day moving average of $330.29 and a 200 day moving average of $305.26. The company has a current ...

Madrigal Pharmaceuticals has a fifty-two week low of $189.00 and a fifty-two week high of $377.46. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.93 and a current ratio of 5.98.

WEST CONSHOHOCKEN, PA – Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company with a market capitalization of $6.66 billion, disclosed a significant change in its executive team ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. The company ...